BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
calcium channel activity
,
Allergy to pollen
,
Stem cell
,
Biofuel
,
Phenobarbital
,
CYP51
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
MAGE-A3
(gene)
Summary
General Info
Body Atlas
Most Correlated Tissues
No tissues found
Explore Body Atlas Results
Disease Atlas
Most Correlated Diseases
Severe combined immunodeficiency disease
Helminth infection
Staphylococcal infectious disease
Infection due to Enterobacteriaceae
Influenza
Explore Disease Atlas Results
Pharmaco Atlas
Most Correlated Compounds
P79 protein, human
Cholesterol
1,3-dichlorobenzene
Deoxycytidine
Serum Albumin
Explore Pharmaco Atlas Results
Knockdown Atlas
Most Correlated Gene Perturbations
XIST
HLF
GTF2I
ANXA2
SGCB
Explore Knockdown Atlas Results
Curated Studies
Most Correlated Studies
Loading...
Explore Curated Studies Results
Literature
Most Relevant Literature
Nuclear overexpression levels of MAGE-A3 predict poor prognosis in patients with prostate cancer.
Re-examination of MAGE-A3 as a T-cell Therapeutic Target.
Cancer testis antigen MAGEA3 in serum and serum-derived exosomes serves as a promising biomarker in …
MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage II…
Regulation of MAGE-A3/6 by the CRL4-DCAF12 ubiquitin ligase and nutrient availability.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes
The Correlation Between MAGE-A3, PRAME Polymorphism and Expression Levels of MAGE-A3 and PRAME in NS…
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01…
Study to Assess Safety and Immune Response of Stage IIB-IV Resected Melanoma After Treatment With MA…
0804 GCC: MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and Neck
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ